Long-acting bronchodilators in COPD: Where are we now and where are we going?

Breathe

Volumn 10, Issue 2, 2014, Pages 111-120

  Cazzola, Mario ^a   Page, Clive ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; ACLIDINIUM BROMIDE; ACLIDINIUM PLUS FORMOTEROL; AZD 2115; BATEFENTEROL; BECLOMETASONE PLUS FORMOTEROL PLUS GLYCOPYRRONIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHF 5259; CICLESONIDE PLUS FORMOTEROL FUMARATE PLUS TIOTROPIUM BROMIDE; CORTICOSTEROID; FLUTICASONE FUROATE PLUS VILANTEROL; FORMOTEROL; FORMOTEROL PLUS GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL PLUS MOMETASONE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PHOSPHODIESTERASE III INHIBITOR; PLACEBO; PT 003; QMF 149; SALMETEROL; SUN 101; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MEDICATION COMPLIANCE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE;

EID: 84903602640     PISSN: 18106838     EISSN: 20734735     Source Type: Journal    
DOI: 10.1183/20734735.014813     Document Type: Article

References (71)

1. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504.
2. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014; 35: 191-201.
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD 2014. www.goldcopd.org
4. National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. National Clinical Guideline Centre, London, 2010. http://guidance. nice.org.uk/CG101/Guidance/pdf/English
5. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
6. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
7. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
8. Tashkin DP. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013; 19: 116-124.
9. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-1192.
10. Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
11. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
12. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of broncho-dilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013; 26: 218-228.
13. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.
14. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784.
15. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
16. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
17. Vogelmeier C, Magnussen H, LaForce C, et al. Profiling the bronchodilator effects of the novel ultra-long-acting b2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011; 5: 345-357.
18. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. Respir Res 2013; 14: 100.
19. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting b-agonists for stable COPD: a systematic review. Chest 2012; 142: 1104-1110.
20. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533.
21. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264-272.
22. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res 2013; 14: 112.
23. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831-838.
24. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010; 27: 150-159.
25. Wu K, Looby M, Pillai G, et al. Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn 2011; 38: 105-119.
26. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013; 14: 775-781.
27. Beier J, Kirsten AM, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013; 10: 511-522.
28. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012; 21: 101-108.
29. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-788.
30. Mahler DA, Buhl R, Lawrence D, et al. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther 2013; 26: 348-355.
31. Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011; 20: 291-298.
32. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012; 106: 989-997.
33. Cazzola M, Rogliani P, Novelli L, et al. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013; 14: 2489-2499.
34. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol 2012; 48: 247-257.
35. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.
36. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013; 22: 117-121.
37. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13-16.
38. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012; 48: 785-794.
39. Cazzola M, Matera MG. Emerging inhaled broncho-dilators: an update. Eur Respir J 2009; 34: 757-769.
40. Matera MG, Page CP, Cazzola M. Novel bronchodi-lators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011; 32: 495-506.
41. Cazzola M, Rogliani P, Segreti A, et al. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012; 21: 1489-1501.
42. Cazzola M, Page CP, Rogliani P, et al. b2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690-696.
43. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013; 26: 307-317.
44. Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43: 72-81.
45. Kerwin EM, Fogarty C, Dunn K, et al. Cardiovascular safety of nebulized glycopyrrolate (SUN-101) compared with tiotropium, ipratropium and placebo in patients with COPD. Am J Respir Crit Care Med 2013; 187: A1483.
46. Orevillo C, St Rose E, Strom S, et al. Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomised, double-blind, placebo-controlled phase 2b study in patients with COPD. Eur Respir J 2011; 38: Suppl. 55, 724s.
47. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
48. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1: 51-60.
49. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single broncho-dilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-1494.
50. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013; 107: 1558-1567.
51. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther 2013; 7: 1201-1208.
52. Scott LJ, Hair P. Umeclidinium/vilanterol: first global approval. Drugs 2014; 74: 389-395.
53. Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med 2013; 187: A4268.
54. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014 [In press DOI: 10.1378/chest.13-1579].
55. Donohue JF, Maleki-Yazdi M, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/ 25 mcg in COPD. Respir Med 2013; 107: 1538-1546.
56. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010; 36: Suppl. 54, 1014s.
57. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat1 inhaler in patients with COPD. Eur Respir J 2012; 40: Suppl. 56, 525-526s.
58. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013; 14: 775-781.
59. Reisner C, St Rose E, Strom S, et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Eur Respir J 2011; 38: Suppl. 55, 150s.
60. Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD. Am J Respir Crit Care Med 2011; 183: A6435.
61. Rennard S, Fogerty C, Fischer T, et al. Pearl therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva Handihaler 18 mg and Foradil Aerolizer 12 mg in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Am J Respir Crit Care Med 2012; 185: A2259.
62. Reisner C, Gotfried M, Denenberg MB, et al. Low doses of Pearl therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva Handihaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. Am J Respir Crit Care Med 2013; 187: A2434.
63. Cazzola M, Lopez-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve broncho-dilator therapy. Eur Respir J 2013; 42: 885-887.
64. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012; 51: 71-95.
65. Norman P. New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and b2 agonists in combination or combined into a single molecule. Expert Opin Investig Drugs 2013; 22: 1569-1580.
66. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-223.
67. Agustí A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily flutica-sone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014; 43: 763-772.
68. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD 2011; 8: 206-243.
69. Kuehn BM. FDA Offers advice to reduce risks of long-acting b-agonists in asthma care. JAMA 2010; 303: 1353-1354.
70. Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol 2014; 114: 365-376.
71. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013; 1: 714-727.